PD-L1 vs TMB vs MSI-H: Which Biomarker Best Predicts Immunotherapy Response?
PD-L1, Tumor Mutation Burden (TMB), and Microsatellite Instability-High (MSI-H) are among the most important biomarkers used to predict whether a cancer patient is likely to benefit from immunotherapy. While MSI-H is generally considered the strongest single predictor of response, no biomarker is perfect. Many oncologists now combine PD-L1, TMB, MSI-H, genomic profiling, and clinical factors to make treatment decisions. In general: MSI-H often provides the strongest prediction of immunotherapy response. High TMB may increase the likelihood of benefit from checkpoint inhibitors. High PD-L1 expression can help identify patients more likely to respond, especially in lung cancer. The best predictions often come from combining multiple biomarkers rather than relying on just one. Why Biomarkers Matter in Immunotherapy Immunotherapy has transformed cancer treatment. Some patients with advanced cancer achieve long-lasting remissions that were once considered impossible. However, not all patien...